Quantcast

Latest AIDS Clinical Trials Group Stories

2013-12-05 23:24:31

ANAC appoints Carole Treston, RN, MPH as first Chief Nursing Officer. Akron, Ohio (PRWEB) December 05, 2013 The Association of Nurses in AIDS Care (ANAC) is pleased to announce the appointment of Carole Treston, RN, MPH as Chief Nursing Officer (CNO). Carole is a visionary nurse leader with significant clinical, senior management and health policy experience and expertise. ANAC’s search for its first CNO included a competitive process that garnered multiple applications which were...

2013-03-08 00:40:23

Multi-site study, led by a Miriam Hospital researcher, could change treatment strategy for these patients A new multi-site study reveals patients with drug-resistant HIV can safely achieve viral suppression — the primary goal of HIV therapy — without incorporating the traditional class of HIV medications into their treatment regimen. Karen Tashima, M.D., director of the HIV Clinical Trials Program at The Miriam Hospital, served as study chair. The AIDS Clinical Trials Group...

2012-07-24 10:10:48

In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease. The drug rifampin, used for treating TB, can lower levels of the HIV medicine efavirenz, so the FDA recommended that patients who weigh more than 50 kg (110 pounds) and who are taking both medications should get 30...

2011-03-03 16:45:39

 A clinical study of anti-HIV/AIDS medicines in the developing world is on the verge of turning "the whole treatment world on its head," according to Dartmouth pediatrician Paul Palumbo. Palumbo, a professor of pediatric medicine at Dartmouth Medical School and executive director of the Dartmouth-affiliated DarDar Pediatric program in Dar-es-Salaam, Tanzania, unveiled the latest findings of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT ) during the...

2010-10-14 13:53:23

Findings from a study, which appear in the Oct. 14, 2010 New England Journal of Medicine, helped influence the World Health Organization (WHO) to change its guidelines this year for the treatment of HIV-infected women who receive a single dose of the antiretroviral drug nevirapine to prevent HIV transmission to their babies. The study demonstrated that the single dose of nevirapine used to prevent mother-to-child transmission of HIV can hamper the drug's effectiveness if it is also used later...

2010-10-14 13:07:46

WHAT: Two studies appearing in the October 14, 2010 New England Journal of Medicine and funded by the National Institutes of Health helped influence the World Health Organization (WHO) to change its guidelines this year for the treatment of HIV infection in certain women and children. The recently updated guidelines affect HIV-infected women who receive a single dose of the antiretroviral drug nevirapine to prevent HIV transmission to their babies, and infants who receive a single dose of...

2010-01-11 06:00:00

BRISBANE, Calif., Jan. 11 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today provided an update on its development program for protease inhibitor RG7227 (formerly referred to as ITMN-191) for the treatment of patients chronically infected with the hepatitis C virus (HCV). The company also reported guidance for the 2010 milestones and key events for RG7227. Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "Today we reported preliminary, top-line...

2009-09-15 10:50:28

Prevention versus treatment? Cost versus efficacy? So go two of the dilemmas looming over Dartmouth's Paul E. Palumbo, M.D., and his fellow researchers in the race to fight HIV and other infectious diseases in the developing world "” especially among women and their young children. "We have this big quandary in resource-limited countries," says Palumbo, a Dartmouth Medical School professor of medicine and pediatrics. "We have a simple approach that is cost-effective, and reduces...

2008-08-07 15:01:00

MEXICO CITY, Aug. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced that a retrospective analysis of six clinical trials found that anti-HIV regimens containing EPZICOM (abacavir + lamivudine) were effective in treatment-naive patients regardless of baseline viral loads. One of the trials analyzed was a large study comparing treatment with regimens containing EPZICOM versus regimens containing Truvada(R) (tenofovir DF + emtricitabine) in treatment-naive patients with both high and low...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related